This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…
Phase: PHASE1, PHASE2 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC